CASR
Extracellular calcium-sensing receptor
As of the edition of 20 October 2026, CASR (extracellular calcium-sensing receptor, UniProt P41180) has 10 drugs tested at it and 9 companies on the list, 5 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P41180
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 31
- Disease areas
- Hormones; Urinary and reproductive; Pregnancy and women's health; Nutrition and metabolism; Bones, joints and muscles; Cancer; Inherited and neonatal; Injuries
- Registered trials of its drugs
- 112
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 1 |
| Went quiet | 5 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Cinacalcet | Marketed | Phase 4 | none listed |
| Etelcalcetide | Marketed | Phase 3 | Ends 2031 |
| Ronacaleret | Went quiet | Phase 2 | none listed |
| Evocalcet | Marketed | Phase 3 | none listed |
| Encaleret | Active | Phase 3 | none listed |
| ASP7991 | Went quiet | Phase 2 | none listed |
| Upacicalcet | Marketed | Phase 3 | none listed |
| ATF-936 | Went quiet | Phase 1 | none listed |
| AXT-914 | Went quiet | Phase 1 | none listed |
| SB-423562 | Went quiet | Phase 2 | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 3 |
| Engaged | 1 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Kyowa Kirin | Route B |
| Merck & Co. | Route A |
| GSK | Route A |
The other 6 companies at CASR
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at CASR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.